India, Nov. 16 -- Prelude Therapeutics Incorporated (PRLD) reported Monday a narrower third-quarter loss as research and development expenses declined.

Company Profile

Prelude is a clinical-stage precision oncology company developing cancer treatments.

Third-Quarter 2026 Financial Results

Net loss narrowed to $12.54 million, or $0.12 per diluted share, from $19.72 million, or $0.26 per diluted share, in the same quarter last year.

Revenue declined to $5.65 million from $6.50 million in the corresponding prior-year quarter.

R&D expenses fell to $14.83 million from $21.71 million, reflecting lower spending on SMARCA2 trials, which were paused in 2025, and reduced employee costs following a workforce reduction in the second half of 2025....